Stockscreener 앱 받기
44.69
1.56%
-0.71
시간 외 거래:
44.91
0.22
+0.49%
Exelixis Inc 주식(EXEL)의 최신 뉴스
Exelixis (EXEL) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
Unlocking Exelixis (EXEL) International Revenues: Trends, Surprises, and Prospects - Yahoo Finance
CoreWeave, Super Micro Computer And Coinbase Are Among Top 11 Large-Cap Gainers Last Week (May 12-May 16): Are The Others In Your Portfolio? - Benzinga
Exelixis raises 2025 revenue guidance by $100M amid strong CABOMETYX market share gains and new NET approval - MSN
Exelixis director George Poste sells $948,957 in stock - Investing.com
Exelixis director George Poste sells $948,957 in stock By Investing.com - Investing.com UK
Exelixis Stock Price, Quotes and Forecasts - Benzinga
Exelixis Q1 2025 Earnings Call Highlights Growth - TipRanks
Guggenheim Raises Price Target for Exelixis (EXEL) Amid Strong R - GuruFocus
EXEL Q1 Earnings Beat, 2025 Sales View Up as Cabometyx Drives Top Line - MSN
Demystifying Exelixis: Insights From 8 Analyst Reviews - Benzinga
Exelixis (EXEL) Target Price Raised by Citigroup Analyst | EXEL Stock News - GuruFocus
Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term - Yahoo Finance
Citi Elevates Price Target for Exelixis (EXEL) to $56 Amid Stron - GuruFocus
Exelixis (EXEL) Receives Increased Price Target, Maintains Stron - GuruFocus
Why Exelixis, Inc. (EXEL) Skyrocketed On Wednesday - MSN
10 Firms Blowing Up by Double Digits Today - Insider Monkey
Exelixis stock target raised to $47 by JMP on strong sales - Investing.com Australia
Exelixis (EXEL) Boosts 2025 Revenue Forecast After Strong Q1 | E - GuruFocus
Exelixis (EXEL) Price Target Raised by Morgan Stanley | EXEL Sto - GuruFocus
Exelixis (EXEL) Maintains Outperform Rating with $40 Price Targe - GuruFocus
U.S. Markets Finished Mixed Wednesday As Exelixis Led, Ubiquiti Lagged - Barron's
Transcript : Exelixis, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 10 - marketscreener.com
Exelixis Is Up Today, Analyst Weighs InExelixis (NASDAQ:EXEL) - Benzinga
Stifel raises Exelixis stock price target to $38 on robust sales - Investing.com Nigeria
Exelixis: A Notable Quarter (NASDAQ:EXEL) - Seeking Alpha
Exelixis Q1 2025 slides: Revenue up 31%, raises FY guidance on CABOMETYX strength By Investing.com - Investing.com South Africa
eToro's Nasdaq debut, Exelixis outlook, Septerna–Novo deal - Yahoo Finance
AbbVie, Nvidia, and Exelixis Lead Market Cap Stock Movers on Wednesday - Investing.com Australia
AbbVie, Nvidia, and Exelixis Lead Market Cap Stock Movers on Wednesday By Investing.com - Investing.com South Africa
Exelixis (EXEL) Boosts 2025 Revenue Guidance After Strong Q1 Per - GuruFocus
Why Exelixis (EXEL) Shares Are Surging Today - GuruFocus
Why Exelixis Stock Is Skyrocketing Today - Yahoo Finance
EXEL Stock Target Raised to $44 by TD Cowen Analyst | EXEL Stock News - GuruFocus
Exelixis Crushes Q1 Earnings Estimates With Strong Cabometyx Sales, Raises 2025 Revenue Guidance - Benzinga
EXEL Stock: Market Uncertainty Highlights Strong Fundamentals | - GuruFocus
Exelixis Announces First Quarter 2025 Financial Results and Prov - GuruFocus
Exelixis, Inc. (NASDAQ:EXEL) Q1 2025 Earnings Call Transcript - Insider Monkey
Exelixis price target raised to $47 from $40 at Morgan Stanley - TipRanks
Exelixis (EXEL) Receives Price Target Boost Following Strong Sal - GuruFocus
Morgan Stanley Adjusts Price Target on Exelixis to $47 From $40, Maintains Overweight Rating - marketscreener.com
Exelixis Hold Rating: Strong Performance and Promising Pipeline Balanced by Fair Valuation - TipRanks
Exelixis (EXEL) Receives Price Target Boost to $46 | EXEL Stock News - GuruFocus
Exelixis price target raised to $46 from $41 at Citizens JMP - TipRanks
Exelixis Q1 2025 Earnings Call Transcript - MarketBeat
Exelixis Inc (EXEL) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
Exelixis Inc (EXEL) Q1 2025 Earnings Call Highlights: Strong Rev - GuruFocus
Exelixis Announces First Quarter 2025 Financial Results and Provides Corporate Update - BioSpace
Invenra Highlights Exelixis’ Initiation of Phase 1 Clinical Study Evaluating XB628, a First-in-Class Bispecific Antibody in Participants with Recurrent Advanced or Metastatic Solid Tumors - BioSpace
Exelixis Q1 2025 slides: Revenue up 31%, raises FY guidance on CABOMETYX strength - Investing.com Nigeria
Exelixis [NasdaqGS:EXEL] Sees US$555 Million Revenue With Earnings Up Sharply - Yahoo Finance
Decoding Exelixis Inc (EXEL): A Strategic SWOT Insight - GuruFocus
0.78%
자본화:
|
볼륨(24시간):